2332-7812

Neurology Neuroimmunology & Neuroinflammation

Ovid Technologies (Wolters Kluwer) - American Academy of Neurology

View prefix report (10.1212)

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1663 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1663 DOIs
2

Add license metadata to 1663 records

License metadata tells indexers and readers how each article may be reused.

High impact1663 DOIs
3

Attach ORCID iDs across 865 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact865 DOIs

DOIs for this ISSN

Showing the top 5 of 1663 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 MOG antibody–positive, benign, unilateral, cerebral cortical… (10.1212/nxi.0000000000000322)
Abstract ORCID License
195.40 402
2 MOG cell-based assay detects non-MS patients with inflammato… (10.1212/nxi.0000000000000089)
Abstract ORCID License
191.90 361
3 Clinical approach to the diagnosis of autoimmune encephaliti… (10.1212/nxi.0000000000000663)
Abstract ORCID License
187.68 317
4 Rituximab in treatment-resistant CIDP with antibodies agains… (10.1212/nxi.0000000000000149)
Abstract ORCID License
179.71 248
5 Does MOG Ig-positive AQP4-seronegative opticospinal inflamma… (10.1212/nxi.0000000000000062)
Abstract ORCID License
178.92 242
6 IgLON5 antibody (10.1212/nxi.0000000000000385)
Abstract ORCID License
176.41 224
7 Apheresis therapies for NMOSD attacks (10.1212/nxi.0000000000000504)
Abstract ORCID License
176.27 223
8 Guillain-Barré syndrome: The first documented COVID-19–trigg… (10.1212/nxi.0000000000000781)
Abstract ORCID License
174.78 213
9 Antibodies to MOG in adults with inflammatory demyelinating… (10.1212/nxi.0000000000000163)
Abstract ORCID License
174.01 208
10 Rituximab before and during pregnancy (10.1212/nxi.0000000000000453)
Abstract ORCID License
173.85 207
11 Antibodies to myelin oligodendrocyte glycoprotein in bilater… (10.1212/nxi.0000000000000040)
Abstract ORCID License
173.70 206
12 Early CNS neurodegeneration in radiologically isolated syndr… (10.1212/nxi.0000000000000102)
Abstract ORCID License
172.41 198
13 Myelin oligodendrocyte glycoprotein antibodies are associate… (10.1212/nxi.0000000000000081)
Abstract ORCID License
172.25 197
14 Does time equal vision in the acute treatment of a cohort of… (10.1212/nxi.0000000000000572)
Abstract ORCID License
172.25 197
15 Autoantibodies to MOG in a distinct subgroup of adult multip… (10.1212/nxi.0000000000000257)
Abstract ORCID License
170.21 185
16 Aquaporin-4 autoimmunity (10.1212/nxi.0000000000000110)
Abstract ORCID License
169.51 181
17 Increased frequency of anti-Ma2 encephalitis associated with… (10.1212/nxi.0000000000000604)
Abstract ORCID License
168.96 178
18 Reduction of CD8 <sup>+</sup> T lymp… (10.1212/nxi.0000000000000076)
Abstract ORCID License
167.85 172
19 B lymphocytes in neuromyelitis optica (10.1212/nxi.0000000000000104)
Abstract ORCID License
167.28 169
20 Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobr… (10.1212/nxi.0000000000000161)
Abstract ORCID License
166.90 167
21 Effects of neuromyelitis optica–IgG at the blood–brain barri… (10.1212/nxi.0000000000000311)
Abstract ORCID License
166.90 167
22 Abnormal brain metabolism on FDG-PET/CT is a common early fi… (10.1212/nxi.0000000000000352)
Abstract ORCID License
166.90 167
23 Neuroleptic intolerance in patients with anti-NMDAR encephal… (10.1212/nxi.0000000000000280)
Abstract ORCID License
166.70 166
24 P2Y12 expression and function in alternatively activated hum… (10.1212/nxi.0000000000000080)
Abstract ORCID License
166.51 165
25 Serum GFAP and NfL Levels Differentiate Subsequent Progressi… (10.1212/nxi.0000000000200052)
Abstract ORCID License
166.31 164
26 Expanded autologous regulatory T-lymphocyte infusions in ALS (10.1212/nxi.0000000000000465)
Abstract ORCID License
165.10 158
27 Next-generation sequencing in neuropathologic diagnosis of i… (10.1212/nxi.0000000000000251)
Abstract ORCID License
164.90 157
28 Systemic inflammatory response and neuromuscular involvement… (10.1212/nxi.0000000000000244)
Abstract ORCID License
164.06 153
29 Neurofilament light in CSF and serum is a sensitive marker f… (10.1212/nxi.0000000000000271)
Abstract ORCID License
163.85 152
30 Antibodies to MOG have a demyelination phenotype and affect… (10.1212/nxi.0000000000000012)
Abstract ORCID License
163.21 149
31 Neurofilament light chain predicts disease activity in relap… (10.1212/nxi.0000000000000422)
Abstract ORCID License
163.21 149
32 The topographical model of multiple sclerosis (10.1212/nxi.0000000000000279)
Abstract ORCID License
160.96 139
33 Both cladribine and alemtuzumab may effect MS via B-cell dep… (10.1212/nxi.0000000000000360)
Abstract ORCID License
160.96 139
34 Neuromyelitis optica spectrum disorders (10.1212/nxi.0000000000000225)
Abstract ORCID License
160.02 135
35 Clinical utility of testing AQP4-IgG in CSF (10.1212/nxi.0000000000000231)
Abstract ORCID License
159.78 134
36 Fecal microbiota transplantation associated with 10 years of… (10.1212/nxi.0000000000000459)
Abstract ORCID License
159.53 133
37 Lipoic acid in secondary progressive MS (10.1212/nxi.0000000000000374)
Abstract ORCID License
158.04 127
38 No evidence for higher risk of cancer in patients with multi… (10.1212/nxi.0000000000000158)
Abstract ORCID License
156.21 120
39 Microstructural visual system changes in AQP4-antibody–serop… (10.1212/nxi.0000000000000334)
Abstract ORCID License
155.94 119
40 Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier d… (10.1212/nxi.0000000000000893)
Abstract ORCID License
155.67 118
41 Dimethyl fumarate treatment alters circulating T helper cell… (10.1212/nxi.0000000000000183)
Abstract ORCID License
155.11 116
42 Profiling individual clinical responses by high-frequency se… (10.1212/nxi.0000000000000555)
Abstract ORCID License
155.11 116
43 Pilot study of a ketogenic diet in relapsing-remitting MS (10.1212/nxi.0000000000000565)
Abstract ORCID License
155.11 116
44 Earlier treatment of NMDAR antibody encephalitis in children… (10.1212/nxi.0000000000000130)
Abstract ORCID License
154.83 115
45 Clinical course and treatment of anti-HMGCR antibody–associa… (10.1212/nxi.0000000000000096)
Abstract ORCID License
154.27 113
46 Randomized phase I trials of the safety/tolerability of anti… (10.1212/nxi.0000000000000018)
Abstract ORCID License
153.10 109
47 CSF herpes virus and autoantibody profiles in the evaluation… (10.1212/nxi.0000000000000245)
Abstract ORCID License
153.10 109
48 Molecular signature of Epstein-Barr virus infection in MS br… (10.1212/nxi.0000000000000466)
Abstract ORCID License
153.10 109
49 Metabolomic signatures associated with disease severity in m… (10.1212/nxi.0000000000000321)
Abstract ORCID License
151.59 104
50 Cryptogenic NORSE (10.1212/nxi.0000000000000396)
Abstract ORCID License
151.59 104